Heparin-binding peptides as novel therapies to stop SARS-CoV-2 cellular entry and infection.

Heparan Sulfate Proteoglycans (HSPGs) are cell surface receptors that are involved in the cellular uptake of pathological amyloid proteins and viruses, including the novel coronavirus; Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS-CoV-2). Heparin and heparan sulfate antagonize the binding of these pathogens to HSPGs and stop their cellular internalization, but the anticoagulant effect of these agents has been limiting their use in the treatment of viral infections. Heparin-binding peptides (HBPs) are suitable non-anticoagulant agents that are capable to antagonize binding of heparin-binding pathogens to HSPGs. Here, we review and discuss the use of HBPs as viral uptake inhibitors and will address their benefits and limitations to treat viral infections. Furthermore, we will discuss a variant of these peptides that is in the clinic and can be considered as a novel therapy in Corona Virus Disease-2019 (COVID-19) infection. Significance Statement The need to discover treatment modalities for COVID-19 is a necessity, and therapeutic interventions such as Heparin-binding Peptides (HBPs), which are used for other cases, can be beneficial based on their mechanisms of actions. In this paper, we have discussed the application of HBPs as viral uptake inhibitors in COVID-19 and explained possible mechanisms of actions and the therapeutic effects.